A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Launched by BRISTOL-MYERS SQUIBB · Nov 30, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how satisfied patients with solid tumors are with their care when they switch from receiving immunotherapy treatment in a hospital to getting that same treatment at home. The goal is to understand if having treatment at home makes patients feel better about their care experience. The study is currently recruiting participants in France, and it includes both men and women aged 18 and older who have already started treatment with specific immune checkpoint inhibitors at the hospital.

To participate, patients must have an advanced solid tumor and must have been approved by their doctor to receive treatment at home. They should also be able to give their consent to take part in the study. Participants will be asked for their feedback on their care experience while receiving treatment at home, which will help improve future cancer care options. If someone is currently part of another clinical trial or has issues with data collection, they won’t be able to join this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female ≥ 18 years old
• • Participants whose oncology specialist has already initiated treatment with immune checkpoint inhibitors (ICIs) in the outpatient hospital setting for an advanced solid tumor (as monotherapy or in combination) or as adjuvant therapy, in an indication approved and reimbursed in France
• • Participants whose oncology specialist has independently of the study defined their eligibility for hospital at home (HAH) before contacting the HAH unit for final admission
• • Participants who provide oral informed consent to participate in the study
• Exclusion Criteria:
• • Participants who have expressed an opposition to their data collection
• • Participants under guardianship
• • Participants taking part in an interventional study for cancer treatment with at least one ICI as an investigational drug